At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- observational study (other)
- How long the study runs
- Study runs about 20 months (dates as stated)
- About the drug or intervention
- observational study — other: This is an observational study based on existing treatments prescribed prior to inclusion.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 700
- Started
- 2025-07-07
- Last checked
- 2025-09
Plain English Summary
What is this study?
- • Testing a new treatment for axial spondylarthritis (axspa)
- • Clinical study - 700 participants
- • This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with axial spondylarthritis (axspa)
Where?
- • Bath - Royal National Hospital for Rheumatic Diseases
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
More detail
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
- ✓Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their...
- ✓Participant is aged 18 years or older at enrolment.
Who cannot take part
- ✗Participation in a clinical trial at enrolment.
See the full criteria
Where Is This Study? (1 UK site)
Royal National Hospital for Rheumatic Diseases
Bath BA1 3NG, United Kingdom
How to Get in Touch
SpA Extend Team
Sponsor contactCONTACT